ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
Promoter Jitendrakumar Patel bought 3,00,150 Amanta Healthcare shares off-market for about Rs 5.40 Crore. Promoter holding rises from 9.02% to 9.79%.
Q2 FY27 revenue ₹83.1 Cr (+17%), PAT ₹4.86 Cr (+26%), EBITDA margin 21.6%. The FY27 ₹420–430 Cr target needs a steep H2 ramp the Q2 run-rate doesn't support.
Q2FY27 revenue ₹83.1 Cr (+17.3% YoY), EBITDA ₹17.95 Cr (21.6% margin), PAT ₹4.86 Cr. H1 revenue ₹151.9 Cr, PAT ₹8.2 Cr. SteriPort Line 3 commissioned September 2026.
Amanta Healthcare reported Q2FY27 revenue of ₹83.13 crore and PAT of ₹4.86 crore, both up sharply YoY. SteriPort Line 3 was commissioned, raising bottle capacity to 11.6 crore.
Amanta Healthcare Ltd reported revenue from operations of ₹83.1 Cr (+17.2% YoY) and net profit of ₹4.9 Cr (+308.3% YoY) for Q2 FY27.
Amanta Healthcare's quarterly shareholding pattern as at 30 Sep 2026 shows promoter and promoter group holding at 31.33%. The filing notes a gift-based promoter group addition, but is a routine periodic disclosure.
Amanta Healthcare's COO Shri Anil Rathi resigned effective October 29, 2026. The departure is disclosed under Regulation 30 of the SEBI Listing Regulations.
Amanta Healthcare intimated a Board Meeting scheduled for 3 Nov 2026 to approve Q1 & H1 FY27 unaudited results. Trading window reopens on 6 Nov 2026.
Amanta Healthcare Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.